Information Provided By:
Fly News Breaks for September 12, 2019
ABBV, AGN
Sep 12, 2019 | 08:26 EDT
UBS analyst Navin Jacob, who this morning upgraded AbbVie (ABBV) to Buy from Neutral, raised his price target on Allergan (AGN) shares to $189 from $172 based on the two companies' deal terms and his revised AbbVie price target of $79. He expects the AbbVie deal to close in the first quarter of 2020, stating that he believes the two have sufficiently addressed possible anti-trust issues with the divestitures of Zenpep and Creon. Jacob keeps a Buy rating on Allergan shares.